AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25213687
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy (routine medications replaced with study regimen to achieve blood pressure <140/90 mm Hg)
Trial: 23462943
Drug: Dairy/Ca (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dairy/Ca (high dairy, ≈ 1400 mg/day Ca, ‐500 kcal/day)
Trial: 23462943
Drug: Control (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (low dairy, ≈ 700 mg/day Ca, ‐500 kcal/day)
Trial: 22263599
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g white sesame seeds daily
Trial: 17288331
Drug: G‐Bond
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐Bond
Trial: 20225466
Drug: One-step adhesives
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-step adhesives (Clearfil Tri‐S Bond and G‐Bond)
Trial: 11479480
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) monotherapy, n = 16
Trial: 11479480
Drug: No antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiplatelet drug (patient control), n = 16
Trial: 11479480
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (including ASA and TIC therapy)
Trial: 7830324
Drug: Free therapy
RxNorm normalized name: Trolamine Salicylate 100 mg in 1 g TOPICAL CREAM [Equate Odor-Free Therapy Arthritis Analgesic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free therapy (by personal physicians without special intervention)
Trial: 25617119
Drug: Aequasyal (oxygenated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aequasyal (oxygenated glycerol triester oral spray)
Trial: 25617119
Drug: Biotene (moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biotene (moisturizing spray)
Trial: 21336679
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy-based weight management program (n=44)
Trial: 14585211
Drug: bivalent HIV
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bivalent HIV gp120 SF2/CM235 vaccine
Trial: 10938184
Drug: Hydroquinidine (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroquinidine (450 mg/day)
Trial: 8751695
Drug: Injection at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection at 4 ml/sec with a 25-sec scan delay
Trial: 8751695
Drug: Injection at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection at 4 ml/sec with a 20-sec scan delay
Trial: 8751695
Drug: Injection at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection at 2 ml/sec with a 30-sec scan delay
Trial: 8751695
Drug: Injection at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection at 2 ml/sec
Trial: 8751695
Drug: Injection at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection at 4 ml/sec
Trial: 1574965
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (r-HuEPO) at a dose of 100 U/kg given intravenously twice weekly for 6 weeks
Trial: 31269914
Drug: High Intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Intensity Interval Training (HIIT) for 8 weeks, 3 times weekly, with an average of 78 ± 5.1 minutes of exercise completed out of 90 minutes.
Trial: 29703226
Drug: Individualised Modular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised Modular Treatment Programme (IMTP) - 10 sessions of individual cognitive behavioural therapy with adolescents and/or parents, focusing on three out of ten available modules.
Trial: 20499357
Drug: Once-yearly i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-yearly i.v. infusion of ZOL 5 mg
Trial: 20499357
Drug: Once-weekly oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly oral ALN 70 mg
Trial: 9850068
Drug: Indomethacin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50 mg twice a day) plus rhEPO (12,000-30,000 units per week)
Trial: 2670659
Drug: Sucralfate suspension,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate suspension, 4 g/day (10 ml four times a day)
Trial: 2449021
Drug: Cimetidine 1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 1.6 g daily
Trial: 6786895
Drug: Cimetidine 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 0.8 g daily
Trial: 27859629
Drug: Intravenous Escherichia
RxNorm normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Escherichia coli lipopolysaccharide (LPS)
Trial: 26118427
Drug: Alisporivir (ALV)
RxNorm normalized name: ALV-001
DrugBank: Alisporivir (DB12139)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisporivir (ALV) 1,000 mg once-daily (QD)
Trial: 26118427
Drug: Alisporivir (ALV)
RxNorm normalized name: ALV-001
DrugBank: Alisporivir (DB12139)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisporivir (ALV) 600 mg QD and ribavirin (RBV)
Trial: 26118427
Drug: Alisporivir (ALV)
RxNorm normalized name: ALV-001
DrugBank: Alisporivir (DB12139)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisporivir (ALV) 800 mg QD and ribavirin (RBV)
Trial: 7500544
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no EPA treatment), n = 10
Trial: 30482392
Drug: Apremilast, 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apremilast, 30 mg twice daily
Trial: 28057030
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (0.5 mmol/kg loading dose for 1 hour, followed by 0.15 mmol/kg/h infusion for 23 hours)
Trial: 25646324
Drug: High whey
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High whey protein-, leucine-, and vitamin D-enriched supplement (150 kcal, 21 g protein; 10×/wk)
Trial: 25646324
Drug: High whey
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High whey protein-, leucine-, and vitamin D-enriched supplement
Trial: 19302265
Drug: Octreotide at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide at doses >=0.5 mg
Trial: 19302265
Drug: Octreotide at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide at doses <0.5 mg
Trial: 11920300
Drug: Combination B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination B vaccine
Trial: 16931265
Drug: Anterior capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior capsule polishing
Trial: 15519082
Drug: Anterior capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior capsule polishing (SI-40 IOL)
Trial: 15519082
Drug: Anterior capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior capsule polishing (Silens6 IOL)
Trial: 8111941
Drug: Atracurium 0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.07 mg.kg‐1
Trial: 8111941
Drug: Pancuronium 0.015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.015 mg.kg‐1
Trial: 21409424
Drug: Midazolam combined
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam combined with fentanyl (50-100 mg)
Trial: 21409424
Drug: Midazolam combined
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam combined with propofol (0.5-2.5 mg/kg)
Trial: 21409424
Drug: Midazolam alone
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam alone (1.0-2.0 mg)
Trial: 3606929
Drug: Nifedipine infusion
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine infusion
Trial: 1682787
Drug: MK-912 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-912 (2 mg)
Trial: 6786131
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume of 6 ml/kg bodyweight
Trial: 10690857
Drug: GH +
RxNorm normalized name: Delsym Cough + Cold Daytime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH + LH-releasing hormone analog (LHRH-A)
Trial: 8475226
Drug: Arginine chlorhydrate
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine chlorhydrate 0.5 g/kg bw IV over 30 min
Trial: 8475226
Drug: Simultaneous DSIP
RxNorm normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous DSIP plus arginine chlorhydrate administration
Trial: 8475226
Drug: Placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV infusion
Trial: 19995493
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care shared between GPs and community pharmacists
Trial: 8579490
Drug: Single transfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single transfusion of allogenic bone-marrow suspension
Trial: 22190137
Drug: 15 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g/day pectin
Trial: 22190137
Drug: 6 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g/day pectin
Trial: 20211323
Drug: Intracoronary BMC
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary BMC therapy
Trial: 17221107
Drug: Fluoxetine (F)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (F) 60 mg/day
Trial: 17221107
Drug: Sibutramine (S)
DrugBank: Sibutramine (DB01105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sibutramine (S) 15 mg/day
Trial: 17221107
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (M) 1,700 mg/day
Trial: 1600598
Drug: 400 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/m2 carboplatin plus 800 mg/m2 cyclophosphamide (level 1)
Trial: 1600598
Drug: 550 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 550 mg/m2 carboplatin plus 1100 mg/m2 cyclophosphamide (level 2)
Trial: 1600598
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of carboplatin and cyclophosphamide
Trial: 1970266
Drug: ICI 141,292
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 141,292 (Visacor) 50 mg
Trial: 1970266
Drug: ICI 141,292
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 141,292 (Visacor) 100 mg
Trial: 1970266
Drug: ICI 141,292
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 141,292 (Visacor) 200 mg
Trial: 1970266
Drug: ICI 141,292
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 141,292 (Visacor) 300 mg
Trial: 30646755
Drug: Device-supported titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Device-supported titration
Trial: 30646755
Drug: Routine titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine titration
Trial: 12046342
Drug: Lamivudine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine (150 mg daily) for 48 weeks
Trial: 31746448
Drug: Immediate Release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate Release (IR) Nifedipine 20 mg
Trial: 31746448
Drug: Sustained Release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained Release (SR) Nifedipine 20 mg
Trial: 25203421
Drug: Sodium Bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Bicarbonate (0.3 g·kg(‐1) + placebo)
Trial: 23361456
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus letrozole
Trial: 10588490
Drug: Nd:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nd:YAG laser treatment (20 pps, 150 mJ) only
Trial: 10588490
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment first, followed by SRP 6 weeks later
Trial: 1679390
Drug: Cadralazine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadralazine (10 mg once daily)
Trial: 31576162
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ibuprofen
Trial: 28173776
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream
Trial: 28324753
Drug: Error augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Error augmentation feedback during training sessions
Trial: 187312
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 1 (2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (CCNU), cyclophosphamide, and methotrexate
Trial: 22949107
Drug: Photohardening therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photohardening therapy (311 nm UVB) for 4-9 weeks
Trial: 21866654
Drug: Unblocking the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unblocking the interior and purgation method (Chinese drugs infused by enteral nutrition tube)
Trial: 15273834
Drug: Methylphenidate treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate treatment for ADHD
Trial: 11158461
Drug: Fluconazole (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (6 mg/kg) administered intravenously or by feeding tube every 72 hours until day of life (DOL) 7, then every 24 hours until DOL 28.
Trial: 7952033
Drug: Single-dose administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose administration of mephenytoin
Trial: 7952033
Drug: Single-dose administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose administration of dextromethorphan
Trial: 7952033
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of mephenytoin and dextromethorphan
Trial: 7952033
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of mephenytoin and caffeine
Trial: 7952033
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of mephenytoin, dextromethorphan, and caffeine
Trial: 31192968
Drug: Conventional laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional laser treatment
Trial: 31978214
Drug: High-dose induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose induction chemotherapy
Trial: 24231592
Drug: Indomethacin submicron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin submicron particle capsules 40 mg 3 times daily
Trial: 24231592
Drug: Celecoxib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg loading dose, then 200 mg BID)
Trial: 20598332
Drug: Propranolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (1 mg/kg per day initially, increased to 4 mg/kg per day within 10 days)
Trial: 20598332
Drug: Propranolol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (4 mg/kg per day)
Trial: 15889234
Drug: Pioglitazone (15-45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (15-45 mg/day)
Trial: 12243600
Drug: Acyclovir 400
RxNorm normalized name: acyclovir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir 400 mg orally 3 times daily
Trial: 12243600
Drug: Valacyclovir 500
RxNorm normalized name: valacyclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 500 mg orally twice daily
Trial: 12243600
Drug: Valacyclovir 250
RxNorm normalized name: valacyclovir 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 250 mg orally twice daily
Trial: 29960741
Drug: Biofeedback therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback therapy in addition to IF electrical stimulation (group A)
Trial: 29960741
Drug: Only biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only biofeedback therapy (group B)
Trial: 24461582
Drug: Etoricoxib (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib (90 mg once daily)
Trial: 15067624
Drug: Levosulpiride 25
RxNorm normalized name: Levosulpiride 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosulpiride 25 mg, 3 times daily
Trial: 2669567
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with standardized Bermuda grass pollen extract
Trial: 23260547
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose autologous muscle derived cells (1, 2, 4, 8 or 16 × 10(6))
Trial: 23260547
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose autologous muscle derived cells (32, 64 or 128 × 10(6))
Trial: 17145529
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with cisplatin plus gemcitabine (PG) (n = 34)
Trial: 7571663
Drug: Cefotaxime plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime plus metronidazole (single dose)
Trial: 7235354
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg, sublingual)
Trial: 7235354
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 mg, sublingual)
Trial: 28219060
Drug: Low-dose Prednisolone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Prednisolone
Trial: 28219060
Drug: Basic therapy
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic therapy only (WAT)
Trial: 21613332
Drug: Adjustment group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjustment group treatment (6 sessions of 2 hours each)
Trial: 21613332
Drug: Adjustment group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjustment group treatment
Trial: 9058850
Drug: Absence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absence of previous antiarrhythmic drug therapy
Trial: 7497561
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg intravenously
Trial: 29700127
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 18F‐alfatide II and 18F‐FDG
Trial: 26675055
Drug: Intramuscular diphereline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular diphereline (twice with a 28‐day interval)
Trial: 26675055
Drug: Intramuscular diphereline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular diphereline
Trial: 22972524
Drug: Desmopressin ODT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin ODT 25-100 µg
Trial: 22972524
Drug: Desmopressin ODT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin ODT 25-50 µg
Trial: 20804428
Drug: Inhalation instruction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation instruction
Trial: 17687648
Drug: Epirubicin 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 90 mg/sqm and paclitaxel 175 mg/sqm plus gefitinib 250 mg daily from day 1 to 21 (Arm B)
Trial: 17687648
Drug: Epirubicin 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 90 mg/sqm and paclitaxel 175 mg/sqm plus placebo (Arm C)
Trial: 16861734
Drug: L-carnitine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (20 mg/kg, intravenously three times a week after each haemodialysis session)
Trial: 9806512
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered during intracavitary brachytherapy
Trial: 9806512
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia with 10% lidocaine solution
Trial: 2539206
Drug: Naloxone (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.3 mg/kg)
Trial: 414205
Drug: Prolonged intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged intravenous infusion of trinitrin for 24 hours in 12 cases and during 5 at 7 days in 27 cases
Trial: 414205
Drug: Prolonged intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged intravenous infusion of trinitrin